TWiV 914: COVID-19 clinical update #121 with Dr. Daniel Griffin

In COVID-19 clinical update #121, Dr. Griffin discusses age as a risk factor for severe disease, updated vaccine boosters for the fall, pediatric infection and antibody seroprevalence in Arkansas over the first year of the COVID-19 pandemic, all-cause maternal mortality in the United States before and during the pandemic, and the effect of 2-week interruption in methotrexate treatment and how it impacts vaccine immunity.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Age as a risk factor for severe disease (NY Times)
• Omicron boosters for the fall (NPR)
• Pediatric infection and antibody seroprevalence in Arkansas (PIDS)
• All-cause US maternal mortality during pandemic (JAMA)
• Effect of 2-week interruption in methotrexate treatment (The Lancet)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• PAXLOVID drug interaction checker (IDSA)
• Contribute to FIMRC fundraiser at PWB 35:42
• Dr. Griffin's treatment guide (pdf)
• Letters read on TWiV 914
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]